NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free DYN Stock Alerts $31.79 -1.28 (-3.87%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$31.54▼$33.2150-Day Range$23.65▼$35.3852-Week Range$6.40▼$35.98Volume553,871 shsAverage Volume1.76 million shsMarket Capitalization$2.78 billionP/E RatioN/ADividend YieldN/APrice Target$40.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Dyne Therapeutics alerts: Email Address Dyne Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside28.3% Upside$40.78 Price TargetShort InterestBearish11.57% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 20 Articles This WeekInsider TradingSelling Shares$5.10 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.03) to ($3.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector461st out of 913 stocksPharmaceutical Preparations Industry209th out of 429 stocks 4.6 Analyst's Opinion Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyne Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.57% of the outstanding shares of Dyne Therapeutics have been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Dyne Therapeutics has recently increased by 8.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYN. Previous Next 3.1 News and Social Media Coverage News SentimentDyne Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Dyne Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for DYN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows5 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,098,485.00 in company stock.Percentage Held by Insiders20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.03) to ($3.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -8.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -8.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 21.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Dyne Therapeutics Stock (NASDAQ:DYN)Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More DYN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYN Stock News HeadlinesJune 15 at 5:10 AM | insidertrades.comSusanna Gatti High Sells 40,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) StockJune 12, 2024 | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 1,590 SharesMay 23, 2024 | insidertrades.comInsider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells 30,426 Shares of StockMay 18, 2024 | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 2,588 SharesJune 14 at 9:23 AM | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Stock Price Up 8.8%June 13, 2024 | globenewswire.comDyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research CongressJune 13, 2024 | americanbankingnews.comOxana Beskrovnaya Sells 2,136 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) StockJune 13, 2024 | americanbankingnews.comSusanna Gatti High Sells 80,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) StockJune 13, 2024 | americanbankingnews.comDyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of "Buy" by AnalystsMay 30, 2024 | globenewswire.comDyne Therapeutics to Present at Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesMay 23, 2024 | bizjournals.comThe Petri Dish: Dyne’s public offering, Kronos’ new CFOMay 22, 2024 | forbes.comUp 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?May 22, 2024 | markets.businessinsider.comDyne Therapeutics Prices Public Offering Of 10.50 Mln Shares At $31.00/shrMay 21, 2024 | globenewswire.comDyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockMay 21, 2024 | seekingalpha.comDyne Therapeutics: Progress Undenied In DM1 And DMD TrialsMay 21, 2024 | finance.yahoo.comAnnouncement of The Shaw Laureates 2024May 20, 2024 | msn.comWhy Is Dyne Therapeutics Stock Soaring On Monday?May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dyne Therapeutics (DYN)May 20, 2024 | finance.yahoo.comWhy Dyne Therapeutics, With A 166% Run This Year, Just Catapulted AgainMay 20, 2024 | globenewswire.comDyne Therapeutics Announces Proposed Public Offering of Common StockMay 20, 2024 | marketwatch.comDyne Therapeutics Shares Rise 23% on Favorable Drug DataMay 20, 2024 | investors.comWhy Dyne Therapeutics, With A 108% Run This Year, Just Catapulted AgainMay 20, 2024 | msn.comPTC Therapeutics, Oragenics, GT Biopharma among healthcare moversMay 20, 2024 | za.investing.comDyne Therapeutics Inc. stock jumps following trial updatesSee More Headlines Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/17/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$40.78 High Stock Price Target$56.00 Low Stock Price Target$22.00 Potential Upside/Downside+28.3%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.92% Return on Assets-90.00% Debt Debt-to-Equity RatioN/A Current Ratio21.83 Quick Ratio21.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book21.34Miscellaneous Outstanding Shares87,380,000Free Float69,234,000Market Cap$2.78 billion OptionableOptionable Beta1.06 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMs. Susanna Gatti High M.B.A. (Age 56)Chief Operating Officer Comp: $754.1kDr. Jonathan McNeill M.D. (Age 39)Chief Business Officer Comp: $662.34kMr. John G. Cox M.B.A. (Age 61)CEO, President & Director Dr. Romesh Subramanian Ph.D. (Age 59)Co-Founder & Advisor Comp: $565.17kMr. Richard William Scalzo M.B.A. (Age 38)Senior VP and Head of Finance & Administration Mr. John Najim M.B.A.Chief Technical OfficerDr. Oxana Beskrovnaya Ph.D. (Age 63)Chief Scientific Officer Comp: $631.08kMs. Amy Reilly (Age 50)Senior VP and Head of Corporate Communications & Investor Relations Mr. Daniel Wilson (Age 52)Senior VP & Head of Legal Ms. Kate MitchellVP & Head of Human ResourcesMore ExecutivesKey CompetitorsDicerna PharmaceuticalsNASDAQ:DRNAAmphastar PharmaceuticalsNASDAQ:AMPHProtagonist TherapeuticsNASDAQ:PTGXFive Prime TherapeuticsNASDAQ:FPRXCalliditas Therapeutics AB (publ)NASDAQ:CALTView All CompetitorsInsiders & InstitutionsSusanna Gatti HighSold 40,000 sharesTotal: $1.33 M ($33.36/share)Oxana BeskrovnayaSold 2,136 sharesTotal: $66,942.24 ($31.34/share)Susanna Gatti HighSold 80,000 sharesTotal: $2.42 M ($30.24/share)Richard William ScalzoSold 1,590 sharesTotal: $48,065.70 ($30.23/share)DekaBank Deutsche GirozentraleBought 20,000 shares on 6/4/2024Ownership: 0.069%View All Insider TransactionsView All Institutional Transactions DYN Stock Analysis - Frequently Asked Questions Should I buy or sell Dyne Therapeutics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DYN shares. View DYN analyst ratings or view top-rated stocks. What is Dyne Therapeutics' stock price target for 2024? 9 brokers have issued 1 year price objectives for Dyne Therapeutics' stock. Their DYN share price targets range from $22.00 to $56.00. On average, they predict the company's stock price to reach $40.78 in the next twelve months. This suggests a possible upside of 28.3% from the stock's current price. View analysts price targets for DYN or view top-rated stocks among Wall Street analysts. How have DYN shares performed in 2024? Dyne Therapeutics' stock was trading at $13.30 at the start of the year. Since then, DYN shares have increased by 139.0% and is now trading at $31.79. View the best growth stocks for 2024 here. Are investors shorting Dyne Therapeutics? Dyne Therapeutics saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 10,110,000 shares, an increase of 8.0% from the May 15th total of 9,360,000 shares. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 7.8 days. View Dyne Therapeutics' Short Interest. When is Dyne Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our DYN earnings forecast. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) released its quarterly earnings data on Thursday, May, 2nd. The company reported ($0.81) EPS for the quarter, hitting analysts' consensus estimates of ($0.81). What ETFs hold Dyne Therapeutics' stock? ETFs with the largest weight of Dyne Therapeutics (NASDAQ:DYN) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).iShares Micro-Cap ETF (IWC). When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Atlas Venture Life Science Advisors LLC (9.18%), RA Capital Management L.P. (5.67%), Vanguard Group Inc. (3.94%), Janus Henderson Group PLC (3.06%), Vivo Capital LLC (1.90%) and Artal Group S.A. (1.74%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DYN) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.